Amsterdam, Netherlands, March 3, 2005-The Translational Genomics
Research Institute (TGen) today announced that Daniel Von Hoff, MD,
Director of Translational Drug Development at TGen and the Director
of the Arizona Health Sciences Center's Cancer Therapeutics Program
is the recipient of the 2005 New Drug Development Organization
Honorary Lecture Award for his significant contributions to
advancing cancer drug therapy.
"We honor Dr. Von Hoff in recognition of his strong personal
commitment and dedication to advancing new treatment options from
the laboratory stage to clinical application, providing hope to
cancer patients worldwide," said Marinus W. Lobbezoo, PhD, Congress
Director of the New Drug Development Organization (NDDO) Research
Foundation in Amsterdam.
As part of this award, Dr. Von Hoff will give the Honorary Lecture
at the third International Symposium on Targeted Anticancer
Therapies (TAT 2005) in Amsterdam. The title of his talk is
"Targeting Contextual Vulnerabilities in Cancer".
"On behalf of my staff and colleagues, I am delighted to have been
selected to receive this award," said Dr. Von Hoff. "I am also
grateful to the NDDO for all its efforts in supporting therapeutic
development in the area of cancer, and to those who have supported
my work over the years."
The lecture was initially established in the early 1990s as the
NDDO Honorary Award, and was a way for NDDO to honor someone who
had been instrumental in advancing the NDDO as an oncology drug
development institute. Later on, the scope of the award was
broadened to include those who have made significant contributions
to advancing drug therapy of cancer in general as nominees.
The TAT 2005 meeting will be the next event in the highly
successful series of Amsterdam-based meetings on new anticancer
drugs. The last two meetings in this series, held in 2002 and 2003,
largely focused on signal transduction modulators. The upcoming
symposium will cover a broader array of innovative anticancer
agents including the most promising ones in preclinical and
clinical development. # # #
About TGen
The Translational Genomics Research Institute (TGen) is a
not-for-profit organization whose primary mission is to make and
translate genomic discoveries into advances in human health.
Translational genomics research is a relatively new field employing
innovative advances arising from the human Genome Project to apply
to the development of diagnostics, prognostics and therapies for
cancer, neurological disorders, diabetes and other complex
diseases.
About the New Drug Development Organization
The New Drug Development Organization (NDDO) also encompasses the
NDDO Research Foundation and NDDO Oncology. The NDDO Research
Foundation aims at contributing to the drug development process in
oncology by the conduct of methodological research and the
organization of top-level scientific meetings on specific drug
development themes and new approaches to cancer treatment. Thus,
NDDO Oncology and the NDDO Research Foundation are two
complementary entities operating under the NDDO umbrella, each with
its specific mission and range of activities.